Albany, New York, September 11, 2017: HER2 breast cancer is one of the hostile types of breast cancer, caused due to over-expression of the HER2 protein. It has been analyzed that being overweight, long term heavy smoking, use of menopausal hormone therapy, physical inactivity and alcohol consumption are seen as the prime factors responsible for increasing risk of breast cancer. Such a scenario has led to the rise in demand for HER2 prevention therapies and antibodies. To study further, a new report has been included in the massive collection managed by Market Research Reports Search Engine (MRRSE). This research report is titled “HER2 Antibodies Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025”, which focuses on the trends and growth expectations for the HER2 antibodies market in the coming years.
As per key research findings, the demand in the global HER2 antibodies market is anticipated to increment at a robust CAGR of 8.6% during the forecast period of 2017 to 2025. Further, the market is estimated to acquire a worth of US$ 21,669.1 mn in 2025, from the previous mark of US$ 10,087.8 mn recorded in 2016. The starting portion of this smart research report focuses on offering a precise overview of the HER2 antibodies market to educate the readers. This section also includes knowledge about various factors such as key market indicators, market dynamics and Porter’s Five Force model, which determines the level of competition in the global HER2 antibodies market.
The later section of the report presents a bifurcation of the overall HER2 antibodies market on the basis of geography. The prime regions targeted in the report are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2016, North America accounted for the major share of 42.7% of the global HER2 antibodies market, followed by Europe. Further, on the basis of therapeutic drugs, the concerned market is segregated into five major classes, viz. Ado-trastuzumab emtansine, Trastuzumab, Lapatinib, Pertuzumab and Everolimus. It has been noted that Trastuzumab account for the noticeable share of 62.1% (revenue) in the HER2 antibodies market.
The final section talks about the major companies from the global HER2 antibodies market. Various players profiled in the report are Pfizer, Inc., Genentech Inc. (F. Hoffmann-La Roche Ltd.), Novartis AG, Abnova Corporation, Bio-Techne (Novus Biologicals, LLC), Celltrion, Inc., InvivoGen, Biocon Limited, and others.
Browse Full Global HER2 Antibodies Market Report with TOC : http://www.mrrse.com/her2-antibodies-market
Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.
90, State Street
Albany, NY – 12207